Icosian Reflections

The crisis through which we are passing

is only part of our day’s work.

IN  WHICH Ross Rheingans-Yoo—a sometime economist, trader, artist, expat, poet, EA, and programmer—writes on things of int­erest.

Reading Feed (last update: May 27)

A collection of things that I was glad I read. Views expressed by linked authors are chosen because I think they’re interesting, not because I think they’re correct, unless indicated otherwise.


(26)

Blog: Don't Worry About the Vase | Covid 5/26/22: I Guess I Should Respond To This Week’s Long Covid Study — re: the study itself, see also this.


(25)

Blog: Open Philanthropy | Open Philanthropy’s Cause Exploration Prizes

Blog: Marginal Revolution | That is now, this was then, Taiwan edition — An editorial from a prominent senator, circa 2001.

Blog: Marginal Revolution | How much are Republicans and Democrats polarized really? — "One question in the online survey…asks about property taxes instead of federal taxes: “Do you consider the amount of property taxes you pay to be too low, about right,

READ MORE

The FDA on Fluvoxamine, round 1

Yesterday, the US FDA responded to a submission for Emergency Use Authorization (that was submitted 146 days earlier) for use of fluvoxamine "for the outpatient treatment of adults 24 years and older...to prevent progression to severe COVID-19 and/or hospitalization" (p. 2).

The FDA's conclusion is:

Due to limitations in the available clinical study results for fluvoxamine in the proposed patient population, lack of compelling in vitro and in vivo data to support the proposed [mechanism of action] of fluvoxamine for the treatment of mild COVID-19 disease, and context of increasingly available therapies with well-characterized [mechanisms of action] and consistent efficacy results in nonhospitalized patients, the FDA cannot reasonably conclude that fluvoxamine may be effective for the treatment of COVID-19. As such, FDA has determined that the criteria for issuance of an EUA are not met at this time.

While the FDA has concluded that the existing clinical data are insufficient to support the issuance of an EUA, these data suggest that further clinical investigation may

READ MORE
1 / 1